Save
Email
Print
ShareSep. 21, 2012 — Although age 45 is used to establish staging in well-differentiated papillary thyroid cancer using the American Joint Committee on Cancer and the International Union Against Cancer TNM Classification of Malignant Tumors (TNM) staging system, a new study presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada, suggests that > 65 may be a more accurate age marker for prognosis.
"While age at diagnosis appears to play a role in papillary thyroid cancer outcomes, new data suggest that a more appropriate age marker for prognosis is > 65 years," said Elizabeth Pearce, MD, of the Boston Medical Center and Program Co-Chair of the ATA annual meeting. "Use of this older age marker would result in down-staging of many patients, reflecting a more favorable prognosis that could avoid potentially unnecessary therapies and allay patients' fears about their longevity."
A review of the literature to determine the origin of this age marker appears to date back to an article by Byar, et al., published in European Journal of Cancer in 1979, that was underpowered and not specific to well-differentiated thyroid cancer. In addition, empiric clinical observations often suggest that patients aged 45 to 64 years appear to have similar long-term outcomes when compared to patients < 45 years of age.
A team of researchers led by Lindsay Bischoff, MD, of the Thomas Jefferson University Hospital in Philadelphia, Pa., thus conducted a study to determine the accuracy of age 45 as a prognostic cut-off. They performed a search of the Surveillance, Epidemiology, and End Result (SEER) database to obtain data for histology-confirmed papillary thyroid cancer. Data were stratified in 5-year categories by age at diagnosis from 20 to 84 years old, with patients 85 years of age and older categorized together. All stages, race/ethnicity groups, and sexes were included. A total of 53, 581 patients were identified with histologically confirmed papillary thyroid cancers.
Researchers found that the overall 5-year survival remained above 90% for all age groups under 65 years. It was not until age 65 years and older that patients had a progressively less favorable prognosis with each advancing age group.
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by American Thyroid Association, via Newswise.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.
more 
